Tag: Verzenio
Eli Lilly Q2 2023 financial results highlight robust 28% revenue growth
Eli Lilly and Company (NYSE: LLY) unveiled their Q2 2023 financials, showcasing a 28% revenue enhancement, predominantly driven by volume growth from Mounjaro, Verzenio, Jardiance, ... Read More
Abemaciclib FDA approval : Lilly breast cancer drug gets regulatory nod
Abemaciclib FDA approval : Eli Lilly and Company (Lilly) has secured the US FDA approval for Verzenio (abemaciclib) to treat metastatic breast cancer in patients ... Read More